PMID- 21311850
OWN - NLM
STAT- MEDLINE
DCOM- 20110610
LR  - 20191112
IS  - 1868-8551 (Electronic)
IS  - 1868-596X (Linking)
VI  - 28
IP  - 1
DP  - 2011
TI  - Skin sensitisation: the Colipa strategy for developing and evaluating non-animal 
      test methods for risk assessment.
PG  - 50-5
AB  - Allergic contact dermatitis is a delayed-type hypersensitivity reaction induced 
      by small reactive chemicals (haptens). Currently, the sensitising potential and 
      potency of new chemicals is usually characterised using data generated via animal 
      studies, such as the local lymph node assay (LLNA). There are, however, 
      increasing public and political concerns regarding the use of animals for the 
      testing of new chemicals. Consequently, the development of in vitro, in chemico 
      or in silico models for predicting the sensitising potential and/or potency of 
      new chemicals is receiving widespread interest. The Colipa Skin Tolerance task 
      force currently collaborates with and/or funds several academic research groups 
      to expand our understanding of the molecular and cellular events occurring during 
      the acquisition of skin sensitisation. Knowledge gained from this research is 
      being used to support the development and evaluation of novel alternative 
      approaches for the identification and characterisation of skin sensitizing 
      chemicals. At present three non-animal test methods (Direct Peptide Reactivity 
      Assay (DPRA), Myeloid U937 Skin Sensitisation Test (MUSST) and human Cell Line 
      Activation Test (hCLAT)) have been evaluated in Colipa interlaboratory ring 
      trials for their potential to predict skin sensitisation potential and were 
      recently submitted to ECVAM for formal pre-validation. Data from all three test 
      methods will now be used to support the study and development of testing strategy 
      approaches for skin sensitiser potency prediction. This publication represents 
      the current viewpoint of the cosmetics industry on the feasibility of replacing 
      the need for animal test data for informing skin sensitisation risk assessment 
      decisions.
FAU - Maxwell, Gavin
AU  - Maxwell G
AD  - Safety and Environmental Assurance Centre, Unilever Colworth, Sharnbrook, UK. 
      Gavin.maxwell@unilever.com
FAU - Aeby, Pierre
AU  - Aeby P
FAU - Ashikaga, Takao
AU  - Ashikaga T
FAU - Bessou-Touya, Sandrine
AU  - Bessou-Touya S
FAU - Diembeck, Walter
AU  - Diembeck W
FAU - Gerberick, Frank
AU  - Gerberick F
FAU - Kern, Petra
AU  - Kern P
FAU - Marrec-Fairley, Monique
AU  - Marrec-Fairley M
FAU - Ovigne, Jean-Marc
AU  - Ovigne JM
FAU - Sakaguchi, Hitoshi
AU  - Sakaguchi H
FAU - Schroeder, Klaus
AU  - Schroeder K
FAU - Tailhardat, Magali
AU  - Tailhardat M
FAU - Teissier, Silvia
AU  - Teissier S
FAU - Winkler, Petra
AU  - Winkler P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - ALTEX
JT  - ALTEX
JID - 100953980
RN  - 0 (Allergens)
RN  - 0 (Biomarkers)
RN  - 0 (Cosmetics)
RN  - 0 (Haptens)
SB  - IM
MH  - Allergens/toxicity
MH  - Animal Testing Alternatives/*methods
MH  - Animals
MH  - Biomarkers
MH  - Cell Line
MH  - Cosmetics/standards
MH  - Dendritic Cells/drug effects
MH  - Dermatitis, Allergic Contact/*pathology
MH  - Haptens
MH  - Humans
MH  - Industry/standards
MH  - Risk Assessment
MH  - Skin/pathology
EDAT- 2011/02/12 06:00
MHDA- 2011/06/11 06:00
CRDT- 2011/02/12 06:00
PHST- 2011/02/12 06:00 [entrez]
PHST- 2011/02/12 06:00 [pubmed]
PHST- 2011/06/11 06:00 [medline]
AID - 10.14573/altex.2011.1.050 [doi]
PST - ppublish
SO  - ALTEX. 2011;28(1):50-5. doi: 10.14573/altex.2011.1.050.